• Theravance Biopharma, Mylan Submit NDA for Revefenacin americanpharmaceuticacreview
    November 14, 2017
    The NDA is supported by the companies' Phase 3 program for revefenacin, which consisted of two replicate pivotal Phase 3 efficacy studies and a 12-month, open-label, active comparator safety study.
  • AbbVie Submits NDA for Elagolix americanpharmaceuticacreview
    September 07, 2017
PharmaSources Customer Service